What happened?
The FDA approved lunsotogene parvec-cwha (Otarmeni) for severe-to-profound sensorineural hearing loss caused by molecularly confirmed biallelic OTOF variants. The product is delivered surgically to the cochlea as a one-time treatment per ear.
Why does it matter?
OTOF-related deafness has a clear single-gene mechanism, making it an unusually direct target for gene replacement. Restoring auditory signalling at the biological source is fundamentally different from compensating for hearing loss with an external device.
How to interpret the evidence
The treatment applies only to a genetically defined subgroup and requires preserved outer hair-cell function and specialist surgical delivery. Durability and long-term developmental outcomes remain important.
What remains uncertain?
This is not a treatment for ordinary age-related, noise-induced or most other forms of hearing loss.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.